Logo

BAROnova's TransPyloric Shuttle Device Receives FDA's Approval for the Treatment of Obesity in Adults

Share this

BAROnova's TransPyloric Shuttle Device Receives FDA's Approval for the Treatment of Obesity in Adults

Shots:

  • The approval is based on ENDObesity II study results assessing TransPyloric Shuttle (TPS) vs sham in 302 patients suffering from obesity with a BMI of 30-40 kg/m2 in 9 centers across the US
  • The ENDObesity II study results: @12mos. loss 3.4x weight (9.5% vs 2.8%); weight loss>10%of body wt. (40% vs 14%); 67% loss >5% of body wt.; improvement in BP- cardiometabolic risk factors & QoL
  • The TransPyloric Shuttle is a device made up of solid silicone involves delayed gastric emptying which results in weight reduction and is designed to be delivered & retrieved endoscopically to reside in the stomach for 1 year

Ref: PRNewswire | Image: General Surgery News

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions